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INTRODUCTION
Recently, interest has increasingly focused on the importance of sleep in the promotion of 
health [1-4]. This interest has been fueled by the fact that over a third of the U.S. population 
reports insufficient sleep [4] and mounting scientific evidence that sleep disturbances are 
associated with increased risks of a number of chronic health conditions, including 
cardiovascular disease, diabetes, and cancer [5-13]. To date, the limited number of published 
studies on sleep duration and cancer risk have yielded provocative, yet highly inconsistent 
results, reporting elevated risks associated with both short and long sleep durations as well 
as no associations for a variety of cancer sites [14-31]. These inconsistencies may partially 
be a reflection of different mechanistic pathways operating for different cancer sites [13]. 
The objective of the current study was to conduct an analysis of sleep duration and risk of all 
cancer sites combined, as well as for the five most commonly-diagnosed cancer sites among 
a large, prospective cohort of California women. Additionally, we evaluated the sleep-
associated risks for cancers of the breast, endometrium and ovary combined, which as a 
group all share an estrogen-mediated etiology [32].
MATERIALS AND METHODS
Study Population
The study population for these analyses was drawn from the California Teachers Study 
(CTS), a large on-going prospective study of female professional school employees in 
California. Participants in the CTS are 133,479 women who responded to a 1995-96 mailing 
to 329,000 active and retired female enrollees in the State Teachers Retirement System 
(STRS). Although information on the characteristics of STRS members is quite limited, the 
sociodemographic profile of CTS members appears to be representative of STRS members 
as a whole [33]. A full description of the CTS cohort is presented elsewhere [33]. The use of 
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human subjects in the CTS has been approved by the Institutional Review Boards at all 
participating institutions and by the California Committee for the Protection of Human 
Subjects, California Health and Human Services Agency.
For the present analyses, CTS participants were excluded (in sequence) for the following 
reasons: lived outside California at baseline (n=8,867); agreed to breast cancer research only 
(n=18); had an unknown history of prior cancer (n=662); had a prior history of invasive 
cancer (n=13,142); asked to be removed from the study after joining (n=1); or had unknown 
or invalid information about sleep duration (n=9,180). The resulting eligible study 
population was comprised of 101,609 women. Other than being slightly older, and less 
likely to be pre-menopausal and report comorbidities, the characteristics of the subjects in 
the current analysis were similar to those of the full CTS cohort.
Outcome Assessment
The CTS cohort is followed annually for cancer diagnosis, death, and change of address. 
State and national mortality files, as well as reports from relatives, are used to ascertain date 
and cause of death. Address changes for continued follow-up are obtained by several 
methods including annual mailings, notifications of moves received from participants, and 
linkages to nationwide consumer reporting companies and the U.S. Postal Service National 
Change of Address database. Cancer outcomes are identified through annual linkages with 
the California Cancer Registry (CCR), a legally mandated statewide population-based 
cancer reporting system. Case ascertainment for the CCR is estimated to be 99% complete 
[34].
For the purposes of our analyses, a woman was considered a cancer case if she was 
diagnosed with a primary invasive carcinoma, identified through the annual linkages of the 
CTS to the CCR, after joining the cohort and before January 1, 2012. Site-specific analyses 
were focused on the five most common invasive cancers diagnosed among CTS participants 
and included: breast (SEER site code = 26000; n=5,053), colorectal (SEER site codes = 
21041-21049, 21051, 21052; n=983), melanoma (SEER site code = 25010; n=749), lung 
(SEER site code = 22030; n=820), and endometrial (ICDO3 code = C54.1, C54.9; n=957). 
The analysis of endometrial cancers excluded 21,464 women identified as having had a 
hysterectomy (either by self-report on their baseline questionnaire or via linkage to 
statewide hospitalization discharge data files) prior to the completion of their baseline 
questionnaire, and women with hysterectomy during the follow-up period were censored at 
the time of their hysterectomy. The “All Sites” group included 12,322 cases of any 
prospectively-diagnosed invasive cancer. We further defined a group of “Estrogen-
mediated” cancers (n=6,458) as incident cases of invasive breast, endometrial, or ovarian 
(SEER site code = 27040; n=443) cancer.
Sleep Duration
Sleep duration was ascertained from the CTS baseline questionnaire, a mailed self-
administered survey, completed in 1995-96 (http://www.calteachersstudy.org/surveys/
BaselineL.pdf), based on response to the question: “In the past year, on average, how many 
hours per day did you spend sleeping (none, <1, 1, 2, 3-4, 5-6, 7-9, 10 or more)?”. 
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Participants who reported fewer than 3 hours of sleep per night were excluded as these were 
considered invalid answers. Sleep duration was then categorized into three groups for 
analysis: 3-6, 7-9, and 10 or more hours per day of sleep.
Covariate Information
Data on potential covariates were gathered from the CTS baseline questionnaire and 
included information on: age at baseline; race/ethnicity; recent physical activity; body mass 
index (BMI); alcohol consumption; smoking status, smoking duration and intensity, age at 
smoking initiation and years since quitting; menopausal status and hormone therapy (HT) 
use at baseline; family history of cancer; age at menarche; parity; breastfeeding history; use 
of non-steroidal anti-inflammatory drugs (NSAIDs); history of colorectal polyps; dietary 
intake of calcium, folate, fiber, iron, vitamin D and fat; total caloric intake; dietary 
consumption of red meat, organ meat, pork, poultry, fish, processed meat, total meat; and 
comorbidity defined by self-report (no/yes) of any of the following conditions: high blood 
pressure, heart attack, myocardial infarction, stroke, or diabetes, or reported taking 
medication to treat high blood pressure. Measures of neighborhood socioeconomic status 
(SES) and urbanization were constructed based on 2000 U.S. census block group data linked 
to the baseline residential address of CTS participants. Methods for constructing these 
neighborhood sociodemographic metrics were developed as part of prior analyses in this 
cohort and are described in detail elsewhere [35,36] . Missing information for each covariate 
was coded as missing and included as a category in the multivariate models.
Follow-up
Follow-up time was calculated as the number of days between the time a woman joined the 
cohort (i.e., the date she completed her baseline questionnaire) and the earliest of four dates: 
the date of her primary invasive cancer diagnosis; the date of her first non-California 
residential address lasting 4 months or longer; the date of her death; or December 31, 2011. 
Women who were diagnosed with in situ cancer during the follow-up period were censored 
at the time of their diagnoses.
Statistical Analysis
Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 
95% confidence intervals (95% CIs) associated with sleep duration, using ages at the start 
and end of follow-up (in days) to define time on study. Sleep duration was modeled as a 
categorical variable, using 3-6, 7-9 (referent group), and 10 or more hours per day of sleep 
as the groupings. All initial models were stratified by age at baseline (in single year 
increments) and adjusted for race/ethnicity. Assessment of important covariates was 
conducted by individually adding each of the potential confounders listed above to these 
initial age-stratified and race/ethnicity adjusted models, and keeping as covariates only those 
variables whose addition changed the regression coefficient for the sleep duration variable 
by 10% or more [37]. This resulted in different multivariate models for each of the cancer 
outcomes, as detailed in the footnote of Table 2. Linear tests for trend across categories of 
sleep duration were performed by using the median value of each category as a continuous 
variable in the models.
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To account for the possibility that sleep duration could be influenced by physiologic changes 
associated with the development of cancer prior to diagnosis, we conducted sensitivity 
analyses in which we repeated our risk analyses after excluding cases who were diagnosed 
within two years of the start of the follow-up period (n=1,488 for all cancer sites) .
All models were run using the PHREG procedure in SAS Version 9.3 (SAS Institute, Cary, 
NC). Statistical significance was based on p-values of < 0.05.
RESULTS
Similar to the CTS cohort as a whole, study subjects were predominantly non-Hispanic 
white (87%) and middle-aged (mean = 52 years; range = 22 to 104 years at baseline). The 
distributions of selected characteristics by categories of sleep duration are presented in Table 
1 (distributions are shown only for those characteristics which were included as covariates in 
risk models for at least one of the site-specific or groups of cancer outcomes). Although 
these characteristics significantly differed across categories of sleep duration (p<0.01), most 
differences were fairly modest. Compared to average sleepers (7-9 hours/day), longer 
sleepers (>10 hours/day) tended to be older, be more likely to be non-white, be less 
physically active, be overweight or obese, abstain from alcohol consumption, have ever 
smoked tobacco, be peri/post-menopausal and have never used hormone therapy, and report 
comorbidities. Overall, characteristics of short sleepers (< 6 hrs/night) tended to be similar 
to those of average sleepers, with the exception that they were slightly more likely to be 
non-white, be less physically-active, be overweight or obese, report comorbidities, and live 
in suburban or urban neighborhoods.
Risk estimates for each of the site-specific and grouped cancer outcomes associated with 
short and long sleep durations are presented in Table 2. Overall, with the exception of lung 
cancer, point estimates generally were near or below one for short sleepers and above one 
for long sleepers; confidence intervals, however, tended to be wide and include 1.0. Tests 
for trend suggested a statistically significant increased risk associated with increasing sleep 
durations for the group of estrogen-mediated (p=0.04) cancers. When the data were stratified 
by menopausal status at baseline, we continued to see an approximate 30% increase in risk 
for the estrogen-mediated cancers associated with long sleeping durations among peri/post 
menopausal women but the number of cases in the long sleep category among pre-
menopausal women was insufficient to evaluate (n=9) (data not shown). When we repeated 
these analyses excluding the cases diagnosed within two-years of baseline, the HRs for long 
sleep duration tended to increase slightly and the HR for the estrogen-mediated cancers 
became statistically significant for the long sleepers (HR=1.31, 95% CI = 1.02 – 1.68 for 
10+ hours/night). While the confidence intervals in these subset analyses generally became 
wider, the test for trend for endometrial cancer became statistically significant (p<0.05).
CONCLUSIONS
The results from these analyses suggest that longer sleep may be associated with increased 
risks of estrogen-mediated cancers only. Our results provided no evidence of risk associated 
with short sleep duration. Our analyses, however, were hindered by a number of limitations 
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that merit some discussion. Perhaps most importantly, our ascertainment of sleep duration 
was based on questions that were asked as part of a series of questions pertaining to physical 
activity, and were not designed specifically to study sleep as a risk factor per se. Thus, 
information on sleep duration was not collected on a continuous scale and the categories of 
duration were primarily designed to capture times for more active activities such as running 
or walking, which are usually performed for shorter time periods than would be typical for 
sleeping. Consequently, the categories of sleep duration that we used in our analyses were 
not ideally-suited to evaluating sleep. We had to use the broad 7-9 hours/day category as our 
referent; a category that only included 7-8 hours/day, which is considered the optimium 
sleep duration for most adults [4], would have been more ideal. If risks associated with 
longer sleep times begin to increase at time intervals of less than 10 hours, this could have 
had the effect of diluting our risk estimates. Furthermore, this categorization resulted in the 
vast majority of our study population (73%) classified into our referent group and relatively 
few cases (generally < 50 cases) in our long sleepers group, further limiting our statistical 
power to detect risks.
Similar to other epidemiologic studies on this topic, our assessment of sleep duration was 
based on self-report, and only on nocturnal sleep, which is likely to have introduced some 
degree of misclassifcation of exposure. While the prospective nature of our study eliminates 
the problem of differential recall bias, we can not discount the possibility of non-differential 
misclassification. There is evidence, however, that one-time self report of habitual sleep 
habits may be reasonably accurate at capturing sleep duration [38,39]. We also did not have 
information on psychosocial factors such as fatigue, anxiety and depression nor on other 
sleep conditions such as apnea or restless leg syndrome that may be important confounders.
Despite these limitations, our study has some notable strengths. Its prospective cohort design 
offers the opportunity to avoid selection and recall biases which can occur in case control 
studies, and the availability of excellent cancer outcome data over the follow-up period of 
nearly 15 lyears, provided substantial numbers of cases, at least for the average and short 
sleepers. The fact that limiting our analyses to exclude cases diagnosed within the first two 
years of follow-up did not substantially change our results suggests that our findings are not 
simply a reflection of reverse causality due to effects of early-stage disease on sleep duration 
prior to clinical diagnosis. Furthermore, while we did not have information on the full 
complement of potential covariates for all of the individual cancer sites we examined, we 
did have information for the most important covariates for breast and other hormonal 
cancers as well as for colorectal cancers, which were the predominant cancers diagnosed in 
our study population.
Our findings are consistent with some reports in the limited but very mixed epidemiologic 
literature on this topic, which has reported null [15,20,26,29], inverse [17-19,24,25,28], and 
direct [17,22,23,26,31] associations between sleep duration and cancer risk. Recent meta-
analyses of these data, while noting substantial heterogeneity in results, concluded that the 
evidence to date does not support an association between sleep duration and overall cancer 
risk [9,11,13]. Other than for breast and colorectal cancers, these meta-analyses, however, 
could not consider other site-specific risks due to the fact that there has not been more than 
one original study published for the other specific cancer sites. Meta-analyses of the three 
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studies of colorectal cancer suggest longer sleep to be associated with a higher risk of 
colorectal cancer (summary rate ratio=1.29; 95% CI: 1.09 – 1.52) [9,13]. Although not 
statistically significant, our finding of an approximate 40% increase in risk of colorectal 
cancer associated with sleep durations of 10+ hours/day, based on only 18 cases, is 
consistent with this conclusion. The literature on breast cancer and sleep is particularly 
mixed with most studies reporting no association with sleep duration [11]. There is some 
very limited evidence, however, that suggests, similar to our own results, longer sleep 
durations may be related to increased breast cancer risk, depending on the subtype of breast 
cancer [26] and how the sleep duration was measured and modeled [22,23]. To our 
knowledge, our study is the first to evaluate and report an increased risk for a group of 
estrogen-mediated cancers. This finding seems to be in contradiction to the results of a meta-
analysis that reported longer sleep was associated with reduced risks of hormone-related 
cancers. The authors of this meta-analysis, however, noted significant heterogeneity 
(p<0.009) in the results, which included studies of men and a broader category of hormone-
related cancer sites than in our study, including cancers of the prostate and thyroid [13].
A number of pathways have been postulated to explain the potential role of sleep in 
carcinogenesis, including its influence on regulation of immune function, insulin 
metabolism, and circadian rhythms mediated by alterations in melatonin secretion 
[1,2,10,40,13]. While it is well beyond the scope of our study to evaluate potential 
mechanisms, our findings of increased risks associated with longer sleep duration seem 
inconsistent with the latter two of these hypothesized pathways. Shorter, not longer, 
durations of sleep have been linked to a number of cancer risk factors related to insulin 
metabolism, including obesity, metabolic syndrome, and diabetes [41-43]. Likewise, the 
carcinogenic effects of circadian disruption are thought to be mediated through the 
suppression of melatonin, an endogenouse hormone with oncostatic and potentially anti-
estrogenic properties that is released primarily during nocturnal sleep and would therefore 
likely exert a protective effect among longer sleepers [44,40,45,46]. Thus, our finding that 
long sleep duration is only associated with estrogen-mediated cancers is not consistent with 
a circadian disruption mechanism mediated by declines in melatonin and associated 
elevations in estrogens. Our finding of an increased risk associated with long sleep durations 
is more consistent with an effect mediated through proinflammatory immune responses. 
Compared to short sleepers, longer sleepers have been shown to have increased serum 
cortisol levels and reduced killer cell activity, both of which may promote carcinogenesis 
[44,2], although the reason why this risk would be confined to the group of estrogen-
mediated cancers is not apparent
In summary, in light of our own findings in the context of the very limited and inconsistent 
body of research on this topic, additional research is clearly warranted. Epidemiologic 
studies that expand beyond considering just sleep duration to include an evaluation of 
metrics of sleep disturbance and quality (including sleep efficiency, sleep onset latency, and 
timing of sleep) would be especially fruitful as would investigations in more diverse 
populations than the CTS that include more people of color, and men Additionally, the use 
of biomarkers to ascertain measures of immune function, circadian disruption and glucose 
metabolism may help to elucidate potential mechanistic pathways, critical towards guiding 
potential future public health interventions. Given that sleep is a potentially modifiable risk 
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factor, a greater understanding of its role in carcinogenesis offers a promising avenue for 
cancer prevention research worthy of pursuit.
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Table 1





b3-6 hrs/day 7-9 hrs/day ≥ 10 hrs/day
N % N %
All 26,440 100 74,211 100 958 100
Age at baseline (years)
    20-29 972 4 3,817 5 30 3
    30-39 3,240 12 10,882 15 79 8
    40-49 7,319 28 20,417 28 135 14
    50-59 7,153 27 17,820 24 159 17
    60-69 4,303 16 11,835 16 192 20
    70-79 2,555 10 6,942 9 158 17
    ≥ 80 898 3 2,498 3 205 21 0.001
Race/Ethnicity
    White 21,293 80 66,109 89 820 86
    Black 1,273 5 1,229 2 30 3
    Hispanic 1,494 6 2,833 4 46 5
    Asian/Pacific Islander 1,474 6 2,110 3 22 2
    Other/unknown 906 3 1,930 2 40 4 <0.001
Physical activity, strenuous & moderate, last 3 years (hrs/week)
    0-1.1 9,700 37 23,513 32 525 55
    1.2-4.1 8,298 31 25,397 34 202 21
    ≥ 4.2 8,442 32 25,301 34 231 24 <0.001
Body Mass Index (kg/m2)
    16-24 14,267 54 45,269 61 477 50
    25-29 6,684 25 17,158 23 237 25
    ≥ 30 4,290 16 9,152 12 160 16
    Unknown/ Outlier 1,199 5 2,632 4 84 9 <0.001
Alcohol consumption (g/day)
    None 9,178 35 22,776 31 414 43
    < 20 14,196 54 41,663 56 385 40
    ≥ 20 1,670 6 6,183 8 89 9
    Unknown 1,396 5 3,589 5 70 8 <0.001
Smoking status
    Never 17,573 66 49,483 67 593 62
    Former 7,161 27 20,925 28 295 31
    Current 1,558 6 3,447 5 63 6
    Unknown 148 1 356 0 7 1 <0.001
Menopausal Status/HT use
c
    Premenopausal 10,240 39 32,131 43 219 23

















b3-6 hrs/day 7-9 hrs/day ≥ 10 hrs/day
N % N %
    Peri/post-menopausal, No HT use 3,475 13 7,940 11 219 23
    Peri/post-menopausal, Past HT use 1,829 7 4,610 6 119 12
    Peri/post-menopausal, Current E 3,531 13 9,183 12 128 13
    Peri/post-menopausal, Current E+P 3,586 14 11,067 15 123 13
    All Other 3,779 14 9,280 13 150 16 <0.001
Co-morbidity
d
    No 19,856 75 59,066 80 575 60
    Yes 6,584 25 15,145 20 383 40 <0.001
Neighborhood Socioeconomic Status
    Lowest quartile 6,818 26 17,076 23 235 25
    2nd quartile 6,210 23 17,673 24 239 25
    3rd quartile 6,285 24 17,619 24 220 23
    Highest quartile 5,893 22 18,036 24 205 21
    Unknown 1,234 5 3,807 5 59 6 <0.001
Neighborhood Urbanization
    Rural/town 2,525 10 8,586 12 120 13
    Non-metropolitan city 6,762 25 20,570 28 258 27
    Suburban/urban 15,921 60 41,255 55 521 54
    Unknown 1,232 5 3,800 5 59 6 <0.001
a
Distributions are presented only for those variables which were included as covariates in risk models for at least one of the site-specific or groups 
of cancer outcomes (see footnote of Table 2).
b
P-value based on the Pearson X2 for all variables except for age and physical activity, for which the Mantel Haenszel X2 was used.
c
Abbreviations: HT=hormone therapy, E=estrogen, E+P=estrogen plus progestin.
d
'Yes' = self-report of any of the following: high blood pressure, high blood pressure medications, heart attack/myocardial infarction, stroke, 
diabetes; 'No' = did not self-report any of those conditions.
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Table 2
Estimated risk associated with sleep duration for selected cancers and groups of cancers among 101,609 




All cases diagnosed from baseline Excluding cases diagnosed within 2-years of 
baseline
# cases HR (95% CI) # cases HR (95% CI)
All Sites 3-6 3,219 0.98 (0.94, 1.02) 2,846 0.98 (0.94, 1.03)
7-9 8,958 1.00 7,863 1.00
10+ 145 1.13 (0.96, 1.33) 125 1.16 (0.97, 1.39)
p(trend)=0.15 p(trend)=0.23
Estrogen-mediated
c 3-6 1,649 0.95 (0.90, 1.01) 1,438 0.96 (0.90, 1.02)
7-9 4,736 1.00 4,091 1.00
10+ 73 1.22 (0.97, 1.54) 64 1.31 (1.02, 1.68)
p(trend)=0.04 p(trend)=0.08
Breast 3-6 1,303 0.97 (0.91, 1.04) 1,139 0.98 (0.92, 1.05)
7-9 3,699 1.00 3,196 1.00
10+ 51 1.13 (0.86, 1.50) 46 1.25 (0.93, 1.68)
p(trend)=0.30 p(trend)=0.42
Colorectal 3-6 269 1.02 (0.89, 1.18) 239 1.02 (0.88, 1.19)
7-9 696 1.00 619 1.00
10+ 18 1.45 (0.91, 2.33) 15 1.42 (0.85, 2.38)
p(trend)=0.90 p(trend)=0.93
Endometrial 3-6 236 0.90 (0.77, 1.04) 198 0.86 (0.73, 1.01)
7-9 708 1.00 612 1.00
10+ 13 1.16 (0.67, 2.01) 11 1.22 (0.67, 2.23)
p(trend)=0.11 p(trend)=0.05
Melanoma 3-6 181 0.99 (0.84, 1.17) 154 0.95 (0.79, 1.14)
7-9 559 1.00 498 1.00
10+ 9 1.44 (0.74, 2.81) 9 1.70 (0.87, 3.32)
p(trend)=0.72 p(trend)=0.36
Lung 3-6 229 1.03 (0.88, 1.20) 209 1.07 (0.91, 1.26)
7-9 581 1.00 511 1.00
10+ 10 0.85 (0.45, 1.60) 8 0.84 (0.42, 1.70)
p(trend)=0.63 p(trend)=0.35
Ovarian
d 3-6 103 0.94 (0.75, 1.17) 95 1.00 (0.79, 1.27)
7-9 318 1.00 273 1.00
10+ 8 1.87 (0.92, 3.80) 6 1.66 (0.74, 3.75)
p(trend)=0.31 p(trend)=0.76
a
Adjusted hazard ratios generated from multivariate age-stratified Cox proportional hazards models as follows: breast cancer adjusted for race/
ethnicity, alcohol consumption and menopausal status/hormone therapy use; colorectal cancer adjusted for race/ethnicity, body mass index (BMI), 
alcohol consumption, menopausal status/hormone therapy use, and cormorbidity; endometrial cancer adjusted for race/ethnicity, BMI, physical 
activity, menopausal status/hormone therapy use, and cormorbidity; melanoma adjusted for race/ethnicity, physical activity, alcohol consumption, 
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menopausal status/hormone therapy use, cormorbidity, smoking status, and neighborhood urbanization and socioeconomic status; lung cancer 
adjusted for race/ethnicity, BMI, physical activity, alcohol consumption, cormorbidity, smoking status, and neighborhood urbanization; all sites 
adjusted for race/ethnicity, BMI, physical activity, alcohol consumption, cormorbidity, smoking status, and menopausal status/hormone therapy 
use; estrogen-mediated sites adjusted for race/ethnicity, BMI and menopausal status/hormone therapy use; ovarian cancer adjusted for race/
ethnicity, BMI and menopausal status/hormone therapy use.
b
Tests for trend calculated by using the midpoints of each sleep duration category and modeling as a continuous variable.
c
Includes invasive cancers of the breast, endometrium and ovary.
d
Excludes women who had an oophorectomy.
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